Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis
Abstract
:1. Introduction
2. Case Report
3. Concluding Remarks
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sormani, M.P.; Schiavetti, I.; Carmisciano, L.; Cordioli, C.; Filippi, M.; Radaelli, M.; Immovilli, P.; Capobianco, M.; De Rossi, N.; Brichetto, G.; et al. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. Neurol.-Neuroimmunol. Neuroinflamm. 2022, 9, e1105. [Google Scholar] [CrossRef] [PubMed]
- Tallantyre, E.C.; Vickaryous, N.; Anderson, V.; Asardag, A.N.; Baker, D.; Bestwick, J.; Bramhall, K.; Chance, R.; Evangelou, N.; George, K.; et al. COVID-19 Vaccine Response in People with Multiple Sclerosis. Ann. Neurol. 2021, 91, 89–100. [Google Scholar] [CrossRef] [PubMed]
- Weinreich, D.M.; Sivapalasingam, S.; Norton, T.; Ali, S.; Gao, H.; Bhore, R.; Xiao, J.; Hooper, A.T.; Hamilton, J.D.; Musser, B.J.; et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with COVID-19. N. Engl. J. Med. 2021, 385, e81. [Google Scholar] [CrossRef] [PubMed]
- Levin, E.G.; Lustig, Y.; Cohen, C.; Fluss, R.; Indenbaum, V.; Amit, S.; Doolman, R.; Asraf, K.; Mendelson, E.; Ziv, A.; et al. Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months. N. Engl. J. Med. 2021, 385, e84. [Google Scholar] [CrossRef] [PubMed]
- Hatzakis, A.; Karabinis, A.; Roussos, S.; Pantazis, N.; Degiannis, D.; Chaidaroglou, A.; Petsios, K.; Pavlopoulou, I.; Tsiodras, S.; Paraskevis, D.; et al. Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. Vaccines 2022, 10, 285. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hoepner, R.; Salmen, A. Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis. Clin. Transl. Neurosci. 2022, 6, 8. https://doi.org/10.3390/ctn6010008
Hoepner R, Salmen A. Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis. Clinical and Translational Neuroscience. 2022; 6(1):8. https://doi.org/10.3390/ctn6010008
Chicago/Turabian StyleHoepner, Robert, and Anke Salmen. 2022. "Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis" Clinical and Translational Neuroscience 6, no. 1: 8. https://doi.org/10.3390/ctn6010008
APA StyleHoepner, R., & Salmen, A. (2022). Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis. Clinical and Translational Neuroscience, 6(1), 8. https://doi.org/10.3390/ctn6010008